Most Read Articles
Pearl Toh, 2 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 2 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.

Antithyroid drugs in early pregnancy up risk of birth defects

20 Dec 2019
The study reaffirms that low-dose aspirin can be considered as a prophylactic of preterm delivery for women at high risk of preeclampsia

Use of antithyroid drug (ATD) therapy in early pregnancy appears to increase the risk of birth defects, suggesting that abnormal maternal thyroid function is not a major risk factor for birth defects, a recent study has shown.

The investigators sought to assess the risk of birth defects associated with the use of ATD in an extended nationwide cohort and the role of abnormal maternal thyroid function in birth cohorts including stored maternal blood samples from early pregnancy.

The study population involved Danish pregnant women and their live-born children, including 1,243,353 children from a Nationwide Register-Based Cohort (NRBC; 1997–2016), 8,830 children from the Danish National Birth Cohort (DNBC; 1997–2003), and 14,483 children from the North Denmark Region Pregnancy Cohort (NDRPC; 2011–2015). Primary outcome was birth defects diagnosed before 2 years of age.

A total of 2,718 (0.2 percent) children in the NRBC had been exposed to ATD in early pregnancy. Birth defects had an overall frequency of 6.7 percent (95 percent confidence interval [CI], 6.7–6.8 percent) in nonexposed children. This rose following exposure to methimazole/carbimazole (9.6 percent; 95 percent CI, 8.2–11.2 percent) and propylthiouracil (8.3 percent, 95 percent CI, 6.7–10.3 percent).

Conversely, the frequency of maternal thyroid dysfunction in early pregnancy was similar in the random cohort and in cases of birth defect in the DNBC (12.4 percent vs 12.6 percent; p=0.8) and the NDRPC (15.1 percent vs 15.4 percent; p=0.8).

“ATD therapy in early pregnancy is associated with birth defects, but more data are needed to substantiate the risk associated with different types of ATD,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 2 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.